Product description

• ProZinc insulin is a sterile aqueous protamine zinc suspension of recombinant human insulin for cats

• ProZinc Diabetes Care Kit contains:

  • U-40 syringes (100 count) to help ensure your clients administer the correct dose with the correct syringe

  • Syringe disposal container to help pet owners properly dispose of needles and syringes

Active ingredients

• Each ProZinc mL contains:

  • Recombinant human insulin 40 International Units (IU)
  • Protamine sulfate 0.466 mg
  • Zincoxide 0.088 mg -Glycerin 16.00 mg
  • Dibasic sodium phosphate, heptahydrate 3.78 mg
  • Phenol (added as preservative)2.50 mg
  • Hydrochloric acid 1.63 mg
  • Water for injection (maximum) 1005 mg

• ProZinc pH is adjusted with hydrochloric acid and/or sodium hydroxide.

Indications for use

ProZinc (protamine zinc recombinant human insulin) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

Administration and dosage

• Use of a syringe other than a u-40 syringe will result in incorrect dosing.

• For subcutaneous injection in cats only.

• Do not shake or agitate the vial.

• ProZinc insulin should be mixed by gently rolling the vial prior to withdrawing each dose from the vial. Once mixed, ProZinc suspension has a white, cloudy appearance. Clumps or visible white particles can form in insulin suspensions: do not use the product if clumps or visible white particles persist after gently rolling the vial.

• Using a U-40 insulin syringe, the injection should be administered subcutaneously on the back of the neck or on the side of the cat.

• Always provide the Cat Owner Information Sheet with each prescription.

• The initial recommended ProZinc dose is 0.1 - 0.3 IU insulin/pound of body weight (0.2 - 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the cat at appropriate intervals and adjust the dose based on both clinical signs and glucose nadirs until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 150 mg/dL and clinical signs of hyperglycemia such as polyuria, polydipsia, and weight loss were improved.

• Further adjustments in the dosage may be necessary with changes in the cat’s diet, body weight, or concomitant medication, or if the cat develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

Prescribing information